칼라리스 테라퓨틱스(KLRS)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.20 (+1.27%), 시가총액 $0.12B, 52주 최저~최고 $2.27 ~ $10.98.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
칼라리스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
칼라리스 테라퓨틱스의 현재 주가는 $3.20 (+1.27%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
칼라리스 테라퓨틱스의 시가총액은 약 $0.12B입니다.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-sta